Skip to main content
Fig. 2 | Cardio-Oncology

Fig. 2

From: Cardiac safety of afatinib: a review of data from clinical trials

Fig. 2

Adjudicated LVEF reductions in the afatinib treatment arms of LL3 and LL1. Six of the 13 patients in the afatinib group for LL3 achieved a full recovery, and 2 patients had a partial recovery. Follow-up ECHOs were not available for 5 patients, 4 of whom had a final LVEF measurement of >50 %. The remaining patient had a final LVEF measurement of 47 %. Three of the 14 patients in the afatinib group for LL1 achieved a full recovery, and 2 patients had a partial recovery. Follow-up ECHOs were not available for 9 patients, 7 of whom had a final LVEF measurement of >50 %. One patient had disease progression and another patient experienced a final LVEF measurement of 46 %. Clinically significant LVEF reductions were examined using established criteria: LVEF <50 and ≥10 % decrease from baseline or LVEF ≥50 and ≥15 % decrease from baseline. Abbreviations: LVEF, left ventricular ejection fraction; LL3, LUX-Lung 3; LL1, LUX-Lung 1; ECHO, echocardiogram; SD, standard deviation. *Mean (SD) percent change from baseline to minimum LVEF during treatment: −24.90 (4.86) for afatinib and −29.30 (0.99) for chemotherapy; mean (SD) percent change from baseline to last LVEF during treatment: −13.95 (10.83) for afatinib and −29.30 (0.99) for chemotherapy. Mean (SD) percent change from baseline to minimum LVEF during treatment: −22.71 (3.33) for afatinib and −31.24 (7.94) for placebo; mean (SD) percent change from baseline to last LVEF during treatment: −16.88 (8.45) for afatinib and −29.38 (11.52) for placebo. Last reported LVEF measurement at database lock

Back to article page